CMS Proposes Rule to Fix MA Directories and Open Up PBM Pricing

The Centers for Medicare & Medicaid Services (CMS), the federal agency that runs Medicare, has proposed a rule to correct inaccurate Medicare Advantage (MA) provider directories and increase transparency around pharmacy benefit managers (PBMs), the companies that negotiate drug prices and collect rebates on behalf of insurers. Healthcare Dive reported the proposal on October 19, 2026, describing it as a vehicle for implementing healthcare provisions included in a federal government funding package passed in February 2026. According to Healthcare Dive's report, most of the reforms in the proposed rule would not take effect until 2028.

The pairing of these two issues is notable. Directory accuracy and PBM pricing are two of the longest-running sources of friction for people shopping for or enrolled in Medicare Advantage. A directory lists which doctors, specialists, and facilities are in a plan's network, but outdated or incorrect listings can lead enrollees to pick a plan based on access to a doctor who is not actually taking new patients or is no longer contracted with that plan. PBMs, meanwhile, sit between drug manufacturers and insurers, negotiating prices and rebates that can shape which drugs land on a plan's formulary and at what cost to the enrollee, even though most of that negotiation happens out of public view.

What CMS Has Proposed, and What's Still Unclear

This is a proposed rule, not a finalized regulation. Proposed rules from CMS typically go through a public comment period before the agency issues a final version, and the specifics, such as exactly what new directory-accuracy standards MA plans would have to meet, or what PBMs would be required to disclose, were not detailed in the October 19, 2026 report beyond the general description of "cleaning up" directories and "shining light on" PBMs. Readers should treat the headline description as directional rather than a complete picture of the rule's mechanics until CMS publishes the full text and, eventually, a final rule.

The 2028 effective date for most provisions also matters for expectations. This proposal traces back to healthcare provisions in a government funding package enacted in February 2026, which suggests Congress set the broad mandate and CMS is now working out the regulatory details. A roughly two-year runway between a proposed rule and full implementation is not unusual for changes that require insurers and PBMs to overhaul reporting systems, but it means none of this will change how Medicare Advantage directories or Part D pricing work during the current enrollment cycle.

Key Takeaway

This is a proposed rule, not a final regulation, and CMS's reported timeline points to most changes taking effect in 2028. Nothing about how Medicare Advantage directories work or how PBMs report pricing changes for Medicare's 2026 Annual Enrollment Period, which runs through December 7, 2026, or for plan year 2027.

What This Means for Medicare Shoppers Right Now

Until a final rule takes effect, the responsibility for verifying network access and drug costs still falls on the enrollee. A few practical steps hold true regardless of how this proposal evolves. First, if you are comparing Medicare Advantage plans for 2027 or any future year, call the specific doctor's or specialist's office directly to confirm they are in-network and accepting new patients under that plan, rather than relying solely on the plan's online directory. Second, if prescription drug costs are a major factor in your decision, check each plan's formulary and estimated out-of-pocket costs through Medicare's Plan Finder tool or with a licensed agent, since PBM-negotiated rebates can affect which drugs are covered and at what tier even before any new transparency rules take effect.

Third, keep an eye on how this proposal develops over the next year or two. A final rule that holds MA plans to stricter directory-accuracy standards, or that requires PBMs to disclose more about rebate arrangements, could eventually change how confidently shoppers can trust a plan's published network and drug pricing. In the meantime, because the reported 2028 timeline leaves a gap, our general guidance for Medicare Plan Path readers remains the same: verify network and formulary details independently each year, and consider working with a licensed agent who can help cross-check a plan's claims against current provider and pharmacy information before you enroll.

This analysis is based on Healthcare Dive's October 19, 2026 reporting on the CMS proposal and does not reflect direct review of the proposed rule's full text. Read the original report at Healthcare Dive for the latest details as CMS moves through the rulemaking process.